|Mr. Robert B. Kay||Exec. Chairman and Chief Exec. Officer||310.73k||N/A||77|
|Mr. Robert L. Erwin||Pres||230k||N/A||64|
|Mr. Terence E. Ryan Ph.D.||Chief Scientific Officer||200k||N/A||62|
|Mr. James P. Mullaney CPA||Chief Financial Officer||N/A||N/A||46|
|Mr. Douglas C. Hicks||Sr. VP of Bus. Devel. & Strategy||N/A||N/A||N/A|
iBio, Inc., a biotechnology company, focuses on commercializing its proprietary plant-based protein expression technologies in the United States and internationally. The companys proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; iBioModulator, a technology platform that is designed to enhance the potency and duration of effect of prophylactic and therapeutic vaccines; and iBio Advanced Technologies. Its therapeutic protein product candidates comprise IBIO-CFB03 for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases; C1 esterase inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement product; and Palivizumab, a monoclonal antibody. The companys vaccine candidates include H1N1 Influenza and H5N1 Influenza viral disease vaccines, which have completed Phase I clinical trials; Yellow Fever viral disease vaccine, which is in preclinical stage; Human Papillomavirus therapeutic vaccine; and malaria and hookworm parasitic pathogen vaccines, which are in Phase I clinical trials. Its biodefense product candidates include Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody. The company has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor. It also has a collaboration and license agreement with FioCruz for the use of its proprietary technology in connection with the development, manufacture, and commercialization of vaccines; and a license and collaboration agreement with Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. iBio, Inc. is based in New York, New York.
iBio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.